Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on August 29, 2013, covering events occurring on August 26, 2013. The filing primarily addresses a significant change in executive leadership and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the compensation package for the newly appointed Chief Executive Officer:
- Base Salary: $350,000 annually.
- Signing Bonus: $150,000 for the remainder of fiscal 2013, payable in Q1 2014.
- Annual Incentive: Up to 200% of base salary contingent on performance objectives.
- Equity Grant: Option to acquire 500,000 shares of common stock, vesting over three years post-spin-off.
Material Changes
The primary material change is the appointment of Jeffrey Duchemin as Chief Executive Officer, effective August 26, 2013. Concurrently, David Green resigned from his role as interim CEO but will remain as President until the completion of the Company's spin-off of its regenerative medicine subsidiary, Harvard Apparatus Regenerative Technology, Inc.
Outlook, Risks, and Management Commentary
The filing details the terms of Mr. Duchemin's employment agreement, including severance provisions. In the event of termination without cause, the Company is obligated to pay 12 months of base salary and accelerate vesting of stock options. In the event of a Change in Control, severance increases to 18 months of base salary with immediate acceleration of all equity awards. The filing notes that Mr. Duchemin's performance objectives may include earnings per share, revenue growth, and cash flow as a percentage of EBITDA, though specific targets are not disclosed.
Investor Verification Checklist
- Verify the status and timeline of the spin-off of Harvard Apparatus Regenerative Technology, Inc., as this triggers the equity grant for the new CEO.
- Review the full Employment Agreement (Exhibit 10.1) for specific definitions of "Cause" and "Change in Control."
- Confirm the impact of the leadership transition on the Company's strategic direction and operational stability.
- Assess the potential cash outflow impact of the $150,000 signing bonus and future incentive payments.